التفاصيل البيبلوغرافية
| العنوان: |
Long-term use of zonisamide in refractory childhood-onset epilepsy. |
| المؤلفون: |
Kluger, Gerhard, Zsoter, Andrea, Holthausen, Hans |
| المصدر: |
European Journal of Paediatric Neurology; Jan2008, Vol. 12 Issue 1, p19-23, 5p |
| مصطلحات موضوعية: |
ANTICONVULSANTS, PEOPLE with mental illness, CHILDHOOD epilepsy, PEOPLE with epilepsy, PEOPLE with intellectual disabilities, PEOPLE with disabilities |
| مستخلص: |
Abstract: This open label study examined the long-term efficacy and safety of zonisamide as adjunctive therapy in mentally retarded and multiple-handicapped patients with severe childhood-onset epilepsy. The study included 24 patients (mean age 12.5 years, range 2–40 years) which had different severe epilepsy syndromes (75% focal, 12.5% generalized, 12.5% refractory status epilepticus) refractory to at least 6 (median 10) anti-epileptic drugs. All patients were followed for at least 18 months after beginning of zonisamide treatment. Mean duration of zonisamide therapy was 55 weeks (range 5–168 weeks) and mean maintenance dosage was 7.7mg/kg/day (range: 4–16mg/kg/day). The patients received an average of 1.9 (range 1–3) concomitant antiepileptic drugs. The initial response rate defined as a⩾50% reduction of seizure frequency after 8 weeks was 58.3% (14 of 24 patients). Four of 14 initial responders developed loss of efficacy during long-term treatment. The retention rate after 18 months was 41.7% (10 of 24 patients). One patient (4.2%) became completely seizure-free after initiation of zonisamide treatment and remained seizure-free for the entire observation period of 18 months. Overall, zonisamide was well tolerated. Side effects were observed in 46% of patients and were mild to moderate. They mostly occurred during titration and subsided in maintenance dosing. Only in two patients (8.3%) zonisamide therapy was discontinued due to side effects (loss of appetite). No serious side effects were observed. These results are similar to the findings of Japanese studies suggesting that long-term use of adjunctive zonisamide therapy may be beneficial for treating mentally retarded, multiple handicapped patients with highly refractory childhood-onset epilepsy. [Copyright &y& Elsevier] |
|
Copyright of European Journal of Paediatric Neurology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder